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Adult T-cell Leukemia/Lymphoma (ATLL) is an aggressive T-cell
malignancy with a poorly understood pathology that manifests
from human T-lymphotropic virus type I (HTLV-1) infected T-cells,
typically after long latency periods (430 years). Current treatment
regimens for ATLL include zidovudine (AZT) and interferon alpha
(IFN-α) combination therapy.1 The established usage of IFN-α in
the treatment of ATLL is largely empirical in origin. The effects of
the other widely used IFN subtype, IFN-β, have not been
thoroughly examined in this setting, even though IFN-β’s more
potent induction of antiproliferative and apoptotic pathways has
been described in solid cancers.2 Few studies have compared the
effects of IFN-α versus those of IFN-β in ATLL and these were
generally performed in cell lines, rather than primary patient
cells.3,4 In vitro experiments with IFN-α using cell lines report
minimal effects of IFN-α on the viability of HTLV-1-infected T-cells
and viral replication, in contrast to the high in vivo response rates
obtained by this therapy.5,6 Reports regarding in vitro and in vivo
activity of IFN-β in this context also seem contradictory: in vitro
experiments showed no antiproliferative action of IFN-β,7 while a
single early in vivo trial using IFN-β reported promising results,
with 50% of six treated patients achieving partial response to
treatment using IFN-β monotherapy.8 The reported success rate of
this IFN-β monotherapy was comparable to early AZT/IFN-α
combination therapy trials where 67% of 24 treated patients
achieved partial response.9
We performed the ﬁrst direct comparison between the
response to IFN-α and IFN-β in ex vivo ATLL patient PBMCs. We
analyzed samples obtained between 2001 and 2007 from 9 men
and 13 women aged 21–78 years (median 47.5), diagnosed as HIV
negative and deﬁnite ATLL with serology, inverted PCR and/or
ﬂow cytometry, at the ‘Hospital Universitário Professor Edgar
Santos’ (HUPES) in Salvador, Bahia, Brazil. Seven of these patients
were classiﬁed as acute, ten as smoldering, three as chronic and
two as lymphoma according to Shimoyama criteria.10 This study
was approved by the Ethics Review Board of HUPES (number
32050106). Data handling and processing was additionally
Figure 1. Boxplots of the effects of IFN-α and IFN-β on measured proliferation, apoptosis and viral protein p19 production in ex vivo PBMCs of
ATL patients. Proliferation was quantiﬁed by [3H] incorporation, apoptosis through ﬂow cytometry of active caspase-3 and viral protein was
quantiﬁed using ELISA. Each sample was treated in parallel in three different conditions: either left untreated, stimulated with 1000 IU of IFN-α
or IFN-β (red and blue, respectively). The data are depicted here as the percentage of the value measured in the corresponding untreated
control condition of the sample. Statistical signiﬁcance of the Friedman rank sum test (*Po0.05, **Po0.01, ***Po0.001) and number of
samples used in the comparison of each condition versus its control (CTR) is indicated underneath the graph. Statistical signiﬁcance of the
difference between IFN-α and IFN-β is depicted above the boxplots. All the datapoints are shown in the graph, excepting two samples that
had no measurable apoptosis in the untreated control condition. These could not be included in this graph, but have been used in the
statistical comparison of signiﬁcance versus control.
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approved by the Medical Ethics Commission of the UZ Leuven
hospital, Belgium (number s57931).
Proliferation, antiviral activity and apoptosis were all measured
in three distinct treatment conditions: cultures were either left
untreated or stimulated with either IFN-α (1000 U/ml) or IFN-β
(1000 U/ml) at the start of the experiment. Bioactivity of IFN-α and
IFN-β was determined using a VSV/Wish bioassay in order to
preclude any bias owing to different antiviral effects of the
interferon subtypes. Neither IL-2 nor PHA were added to the
ex vivo cultures in order to approximate in vivo conditions as
closely as possible. Proliferation was measured by [3H] thymidine
incorporation assay in the cultures of ex vivo PBMCs of 19 patients.
Active caspase-3 was measured by ﬂow cytometry (FACSort,
BD Biosciences, Franklin Lakes, NJ, USA) using a CBA apoptosis kit
(BD Biosciences). HTLV p19 protein levels in PBMC 48-h culture
supernatants were measured using the HTLV-I/II p19 antigen ELISA
(ZeptoMetrix, Buffalo, NY, USA), according to the manufacturer’s
instructions. Detailed methods as well as all experimental results
are provided as supplementary materials.
Unless otherwise noted, Bonferroni-corrected, nonparametric
Friedman rank sum tests were used to test for statistically
signiﬁcant differences between the three experimental conditions.
The results of these tests are summarized in Figure 1. IFN-α
caused a small but signiﬁcant 24 ± 36% (mean± s.d.) decrease in
proliferation in the 19 examined samples, whereas IFN-β treatment
decreased proliferation signiﬁcantly by 47 ± 58% (mean± s.d.).
Direct comparison of IFN-α vs IFN-β treatment conditions shows
that IFN-β exerted superior antiproliferative activity. Caspase 3
activation, measured in six samples, showed an increase in
apoptosis for both IFN subtypes, but IFN-β showed a signiﬁcantly
higher increase in apoptosis than IFN-α (12.8 ± 7.2 and
4.9 ± 7.1 pg/ml, mean ± s.d., respectively). Fourteen out of 16
tested samples had detectable virus production in the super-
natants of 48-h cultures. Viral p19 levels varied strongly between
patient samples, ranging from 4.8 to 10792.7 pg/ml (mean± s.d.,
2131.3 ± 3796.9) in the control condition. Both IFN-α and IFN-β
treatments resulted in comparable reductions in viral p19 levels
when contrasted with the untreated control condition (a mean± s.
d. decrease of 49 ± 32% versus 69 ± 70%), suggesting that the
observed differential effects of the two IFN types on proliferation
and apoptosis do not stem from a differential impact on viral
replication.
Sample quantities did not allow for the puriﬁcation of leukemic
cells, so their relative contribution to the composition of the
examined PBMCs could not be determined. Additionally, at the
time of patient recruitment and sample processing for ex vivo
experiments, TSLC1/CADM1 had not yet been described as a
reliable ﬂow cytometry marker for HTLV-1 infected and ATLL
leukemic cells.11,12 As such, we could not determine whether the
observed differential effects of IFN-α and IFN-β take place in
leukemic, HTLV-1 infected non-leukemic or HTLV-1-negative cells.
However, in a re-analysis of the data comparing the effects of IFN-
α and IFN-β on proliferation in ATLL subtypes with high
percentages of circulating ATLL cells (that is, acute and chronic
subtypes, n= 8), the differences remained signiﬁcant (P= 0.004). In
contrast, patients with low percentages of circulating ATLL cells
Figure 2. Selected gene set enrichment analysis results. The impact of IFN-α treatment (a) and IFN-β treatment (b) on four selected gene sets
relevant to ATL associated with interferon signaling (red), apoptosis (yellow), p53 signaling (green) and NF-κB signaling (blue). The top graph
depicts the running Enrichment Score (ES) graphed versus the rank of the gene when ordered by the t-statistic of their differential expression
(Untreated vs IFN treatment) result, which is depicted at the bottom.
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(that is, lymphoma and smoldering subtypes, n= 11) did not show
these signiﬁcant differences (P= 0.36), suggesting that the
differential effects occur in the leukemic cells. Viral p19 protein
measurements show no signiﬁcant differences between IFN-α and
IFN-β treatments in these subgroups (P= 0.32 and P= 0.71 for high
and low ATLL cell percentage subgroups, respectively).
These ﬁndings were complemented with microarray analysis.
Both the preprocessed and the raw data from the microarray
experiments are available at the National Center for Biotechnology
Information Gene Expression Omnibus under accession number
GSE85487. Paired differential expression analysis comparing
control, IFN-α- and IFN-β-treated samples of six patients shows
that the IFN-β response can be regarded as both broader and
stronger than the IFN-α response: all but two of the signiﬁcantly
IFN-α regulated genes were regulated more strongly by IFN-β
(one-sided, paired t-test, Po0.005).
Although the mechanism behind the AZT/IFN-α treatment in
ATLL has not been fully elucidated,6,13 recent research pointed to
the protein kinase R (PKR or EIF2AK2) gene as a critical gene in the
antiviral response and the activation of the p53 pathway and the
induction of apoptosis as key components in its mechanism.14 We
report a superior effect of IFN-β on all of these processes. First, our
microarray results show that IFN-β affects PKR gene transcription
more strongly than IFN-α (21 vs 15% increase, P= 0.04). Second,
Gene Set Analysis (GSA) shows that the enrichment of the
canonical apoptosis pathway that is prominent in the IFN-β
condition is absent in the IFN-α condition (Figure 2). Third, while
p53 gene expression (TP53) is not signiﬁcantly affected by either
IFN-α or IFN-β treatment, in agreement with the post-
transcriptional stabilization of p53 by AZT,15 GSA shows that the
p53 pathway is more strongly activated by IFN-β than by IFN-α
(Figure 2). Finally, in agreement with the results of Kinpara et al.,14
GSA of the IFN-α treatment microarray results revealed a modest
downregulation of the NF-κB pathway, which has been identiﬁed
as integral to the ATLL transcriptome in a recent integrated omics
analysis in a large number of patients.16 In contrast to the IFN-α
effects, IFN-β treatment upregulated NF-κB pathway activation.
Combined, these results suggest that IFN-β has a greater impact
on the crucial elements of the AZT/IFN-α treatment mechanism
than IFN-α, already making a strong case for possible clinical trials
using IFN-β or AZT/IFN-β. But perhaps the clearest argument in
favor of clinical trials using IFN-β in ATLL is that most of the genes
in the in vivo AZT/IFN-α response gene set reported by Alizadeh
et al.13 respond more strongly to IFN-βmono-stimulus than to IFN-
α mono-stimulus in these ex vivo PBMCs (Supplementary Table 2).
Other preclinical cancer models have previously shown superior
antiproliferative and proapoptotic effects of IFN-β when compared
with IFN-α2,17 but, to our knowledge, this is the ﬁrst time that
these differential effects have been reported in ex vivo PBMCs of
leukemia/lymphoma patients. Due to three strong similarities with
observations made by Sancéau et al.17 in a preclinical Ewing
Sarcoma model, we hypothesize that other leukemias with a
functional or wild-type p53 could also be more sensitive to the
proapoptotic effects of IFN-β as compared with IFN-α. First, the
four cell lines examined in their study proved to be more
susceptible to the antiproliferative effects of IFN-β than to those of
IFN-α, similar to the PBMCs of ATLL patients used in the present
report. Second, IFN-β, but not IFN-α, induced apoptosis in the two
cell lines with wild-type p53 but not in those with mutant p53,17
which is in line with p53’s mutant status as a predictor of poor
response to AZT/IFN-α treatment15 and the p53-dependence AZT/
IFN-α-induced apoptosis.14 Third, Sancéau et al.17 showed that
IFN-β-induced apoptosis was mediated by IRF1, which is also
associated with AZT/IFN-α treatment response in ATLL.13
In conclusion, we performed the ﬁrst comprehensive analysis
comparing the effects of IFN-α and IFN-β on ex vivo PBMCs of
ATLL patients. Our observations suggest that IFN-β is a worthwhile
candidate for clinical trials in ATLL and is also worth investigating in
other leukemic contexts where IFN-α has shown modest success.
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